240 related articles for article (PubMed ID: 27011176)
21. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin.
Bhandari KH; Newa M; Uludag H; Doschak MR
Int J Pharm; 2010 Jul; 394(1-2):26-34. PubMed ID: 20412845
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases.
Wang G; Mostafa NZ; Incani V; Kucharski C; Uludağ H
J Biomed Mater Res A; 2012 Mar; 100(3):684-93. PubMed ID: 22213565
[TBL] [Abstract][Full Text] [Related]
23. Designing proteins for bone targeting.
Gittens SA; Bansal G; Zernicke RF; Uludağ H
Adv Drug Deliv Rev; 2005 May; 57(7):1011-36. PubMed ID: 15876401
[TBL] [Abstract][Full Text] [Related]
24. Raloxifene preserves phenytoin and sodium valproate induced bone loss by modulating serum estradiol and TGF-β3 content in bone of female mice.
Anwar MJ; Radhakrishna KV; Sharma A; Vohora D
Eur J Pharm Sci; 2014 Oct; 62():219-26. PubMed ID: 24880111
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates: focus on inflammation and bone loss.
Iannitti T; Rosini S; Lodi D; Frediani B; Rottigni V; Palmieri B
Am J Ther; 2012 May; 19(3):228-46. PubMed ID: 22549638
[TBL] [Abstract][Full Text] [Related]
26. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
Shi J; Xiao Z; Kamaly N; Farokhzad OC
Acc Chem Res; 2011 Oct; 44(10):1123-34. PubMed ID: 21692448
[TBL] [Abstract][Full Text] [Related]
27. Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?
Liu J; Zhang H; Dong Y; Jin Y; Hu X; Cai K; Ma J; Wu G
Med Hypotheses; 2014 Dec; 83(6):694-6. PubMed ID: 25459136
[TBL] [Abstract][Full Text] [Related]
28. Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy.
Su K; Shi X; Varshney RR; Wang DA
Expert Opin Drug Deliv; 2011 Jan; 8(1):113-26. PubMed ID: 21174607
[TBL] [Abstract][Full Text] [Related]
29. [Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].
Yamamoto S; Ei I; Narita I
Clin Calcium; 2016 Sep; 26(9):1301-7. PubMed ID: 27561345
[TBL] [Abstract][Full Text] [Related]
30. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
31. Emerging drugs for the treatment of bone metastasis.
Pantano F; Iuliani M; Zoccoli A; Fioramonti M; De Lisi D; Fioroni I; Ribelli G; Santoni M; Vincenzi B; Tonini G; Santini D
Expert Opin Emerg Drugs; 2015; 20(4):637-51. PubMed ID: 26113304
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic approaches to myeloma bone disease: an evolving story.
Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
[TBL] [Abstract][Full Text] [Related]
33. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery.
Damiano MG; Mutharasan RK; Tripathy S; McMahon KM; Thaxton CS
Adv Drug Deliv Rev; 2013 May; 65(5):649-62. PubMed ID: 22921597
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological diversity among drugs that inhibit bone resorption.
Russell RG
Curr Opin Pharmacol; 2015 Jun; 22():115-30. PubMed ID: 26048735
[TBL] [Abstract][Full Text] [Related]
35. Novel bone-targeted strategies in oncology.
Vallet S; Smith MR; Raje N
Clin Cancer Res; 2010 Aug; 16(16):4084-93. PubMed ID: 20643782
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy.
Johnsen KB; Gudbergsson JM; Skov MN; Pilgaard L; Moos T; Duroux M
Biochim Biophys Acta; 2014 Aug; 1846(1):75-87. PubMed ID: 24747178
[TBL] [Abstract][Full Text] [Related]
37. Poly(γ-benzyl-L-glutamate)-PEG-alendronate multivalent nanoparticles for bone targeting.
de Miguel L; Noiray M; Surpateanu G; Iorga BI; Ponchel G
Int J Pharm; 2014 Jan; 460(1-2):73-82. PubMed ID: 24211357
[TBL] [Abstract][Full Text] [Related]
38. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
39. Targeted anticancer therapy: overexpressed receptors and nanotechnology.
Akhtar MJ; Ahamed M; Alhadlaq HA; Alrokayan SA; Kumar S
Clin Chim Acta; 2014 Sep; 436():78-92. PubMed ID: 24836529
[TBL] [Abstract][Full Text] [Related]
40. [Bone targeted therapies: new agents].
Barth C; Massard C; Vignot S
Bull Cancer; 2013 Nov; 100(11):1215-21. PubMed ID: 24158596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
